RxDoctor Payments Data

Sarada Uppuluri, MD

Cardiovascular Disease · Indianapolis, INNPI 1477679694

Payments from drug & device makers

$1,982in general payments, 2019–2025

Across 69 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$527
  • Pfizer$357
  • AstraZeneca$253
  • Boston Scientific$212
  • Novartis$136
  • Regeneron Healthcare Solutions, Inc.$68
  • plus $428 from 15 others

What the payments were for

  • Food & beverage$1,97099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,982 in reported general payments places this provider in the 40th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$136,455
Medicare patients
1,960
Services billed
3,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$230,897
Repatha SureclickEvolocumab131$183,632
XareltoRivaroxaban83$116,842
EntrestoSacubitril/Valsartan36$51,886
Praluent PenAlirocumab21$26,828
Metoprolol Succinate448$5,622
Ranolazine ErRanolazine43$4,235
Rosuvastatin Calcium218$3,509
Ezetimibe129$3,235
Valsartan102$2,592
Atorvastatin Calcium355$2,481
Amiodarone Hcl36$2,102
ClopidogrelClopidogrel Bisulfate186$1,961
Nebivolol Hcl26$1,404
Amlodipine Besylate244$1,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$357$230,897186 claims
Johnson & JohnsonXarelto$66$116,84283 claims
NovartisEntresto$136$51,88636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →